Concord Biotech Limited vs Alkem Laboratories Limited
Last updated: 24 October 2026
MoneyDock presents a comparative analysis between Concord Biotech Limited (CONCORDBIO.NS) and Alkem Laboratories Limited (ALKEM.NS), two prominent players in the Indian pharmaceutical and biotechnology sector. While Concord Biotech specializes in fermentation-based biopharmaceutical products, catering to therapeutic areas such as immunosuppressants, oncology, and anti-infectives, Alkem Laboratories is a leading Indian pharmaceutical company with a strong presence in various therapeutic segments including anti-infectives, pain management, and dermatology, both domestically and internationally. This comparison aims to provide investors with a data-driven perspective on their recent performance and market standing, leveraging key financial metrics to help inform investment decisions within the dynamic healthcare industry.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Alkem Laboratories Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹4947.00 |
| 52W High | ₹1579.40 | ₹5867.00 |
| 52W Low | ₹1014.80 | ₹4947.00 |
| 1-Year Return | -7.65% | -12.11% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: When assessing valuation, it's challenging to draw definitive conclusions as the Trailing P/E and Market Cap data are not available for either Concord Biotech or Alkem Laboratories. Without these critical metrics, a direct comparison on traditional valuation multiples is not possible. Investors would need to delve deeper into their financial statements for other valuation metrics like Price-to-Book or EV/EBITDA, which are beyond the scope of the provided data.
Returns: In terms of 1-Year Returns, Concord Biotech Limited has performed relatively better, albeit still in negative territory, with a return of -7.65%. Alkem Laboratories Limited has seen a more significant decline over the past year, with a return of -12.11%. This suggests that Concord Biotech has managed to limit its losses more effectively than Alkem Laboratories over the recent 12-month period, making it the stronger performer in terms of short-term returns among the two, given the available data.
Stability: Evaluating stability from the provided data primarily involves looking at the 52-week price range in relation to the current price. Alkem Laboratories Limited's current price of ₹4947.00 is precisely at its 52-week low of ₹4947.00, indicating that it is currently trading at the lowest point within its last year's price spectrum. This might suggest a period of significant bearish sentiment or underlying challenges. In contrast, Concord Biotech Limited's current price of ₹1229.30 is above its 52-week low of ₹1014.80, and below its 52-week high of ₹1579.40, showing more fluctuation but not currently at its lowest point. This might imply a slightly more stable price trend or at least a recovery from its absolute lows, relative to Alkem. However, being at a 52-week low for Alkem could also signal a potential buying opportunity for some, or further downside for others, depending on future prospects. Without deeper fundamental analysis, it's hard to definitively label one as more 'stable' purely on price points, but Alkem's current position at its 52-week low warrants closer inspection regarding its stability.
MoneyDock Verdict
Aggressive Investor: For aggressive investors looking for potential turnaround stories or value plays, Alkem Laboratories, trading at its 52-week low, might present an interesting, albeit higher-risk, proposition if its fundamentals are strong and a rebound is anticipated. However, the lack of valuation metrics makes it a speculative bet based solely on price. Concord Biotech shows comparatively less downside in 1-year returns, which might appeal to those seeking relative strength in a challenging market, but it too lacks crucial valuation data for a firm aggressive play.
Conservative Investor: Conservative investors would find it difficult to make a well-informed decision based on the provided data due to the absence of crucial valuation metrics like P/E ratio and Market Cap. Both companies have negative 1-year returns, indicating recent market headwinds. Alkem's current position at its 52-week low adds an element of uncertainty. For conservative investors, neither stock stands out as a clear choice for capital preservation or steady growth without a more comprehensive fundamental analysis.
Long-term SIP Investor: Long-term SIP investors often benefit from averaging out costs, especially when stocks are down. Concord Biotech, with a comparatively less severe 1-year negative return, might offer a slightly better entry point for long-term averaging if its growth prospects are robust. Alkem Laboratories, at its 52-week low, could be attractive for long-term investors if they believe in the company's intrinsic value and future recovery, as buying low is key to SIP success. However, without P/E and Market Cap, the underlying financial health and growth potential for the long term are not clear. Thorough due diligence beyond these metrics is essential for both companies for a long-term SIP strategy.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.